{
    "clinical_study": {
        "@rank": "141261", 
        "arm_group": {
            "arm_group_label": "OPB-111077", 
            "arm_group_type": "Experimental", 
            "description": "orally, once daily"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I, open label, non randomized, multicenter study designed to investigate the\n      safety and tolerability of escalating doses of OPB-111077 administered orally, once daily in\n      subjects with advanced HCC."
        }, 
        "brief_title": "A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histopathologically or clinically diagnosed HCC by Korean Liver Cancer Study Group\n             (KLCSG) guidelines.\n\n          2. Subject who has advanced HCC\n\n          3. Documented evidence of unresponsiveness to, intolerance to, or ineligibility for\n             sorafenib, or unavailability of appropriate sorafenib treatment\n\n          4. Male or female subject, age at consent \u226520 years and \u226475 years.\n\n          5. Life expectancy \u226512 weeks.\n\n          6. Subjects who agree that they or their partner(s) will practice contraception during\n             the study period and 3 months (12 weeks) after the completion of study treatment.\n\n          7. Subjects informed of the diagnosis of advanced HCC who are fully informed about the\n             content of the study by the Investigator using the written consent form, and give\n             written consent to participate in the study of their own free will.\n\n        Exclusion Criteria:\n\n          1. Past liver transplantation\n\n          2. Uncontrollable hepatic encephalopathy or ascites\n\n          3. Presence of brain metastases\n\n          4. Clinically significant gastrointestinal bleeding in past 6 months or current active\n             gastrointestinal bleeding.\n\n          5. Primary malignancy other than HCC\n\n          6. Human immunodeficiency virus (HIV) infection\n\n          7. Severe or poorly controlled complication that may affect the conduct or results of\n             the study.\n\n          8. Use of Interferon preparation within 4 weeks (28 days) before start of study\n             treatment in the present study.\n\n          9. Pregnant, nursing, or possibly pregnant women, or women desiring to become pregnant\n             during the study period\n\n         10. Other cases judged by the Investigator to be ineligible for participation in the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942083", 
            "org_study_id": "317-12-001", 
            "secondary_id": "There is no secondary ID."
        }, 
        "intervention": {
            "arm_group_label": "OPB-111077", 
            "intervention_name": "OPB-111077", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul & Gyeonggi-Do", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "gb122@otsuka.co.kr", 
            "last_name": "GeumBo Lee", 
            "phone": "+82232879252"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety (MFDS)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022 Number of participants with Adverse Events as a Measure of Safety and Tolerability", 
                "measure": "Safety and tolerability of OPB-111077", 
                "safety_issue": "Yes", 
                "time_frame": "Within the first cycle [24 days]"
            }, 
            {
                "description": "\u2022 The highest dose that does not lead to discontinuation of dose escalation is defined as the MTD.", 
                "measure": "To investigate the maximum tolerated dose (MTD) of OPB-111077", 
                "safety_issue": "Yes", 
                "time_frame": "Within the first cycle [24 days]"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942083"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following PK parameters (Cmax (maximum observed concentration), AUC(area uder the concentration time curve from zero), tmax (Time to maximum plasma concentration), etc.) will be determined using a non-compartmental methods.", 
                "measure": "Pharmacokinetics (PK) properties of OPB-111077 and its metabolites.", 
                "safety_issue": "No", 
                "time_frame": "Within the first cycle [24 days]"
            }, 
            {
                "description": "Assessment will be conducted at Screening, end of Cycle 1, end of Cycle 2, end of every 2 cycles thereafter, at the Early Termination (discontinuation) Visit.", 
                "measure": "Tumor response measured by RECIST(Response Evaluation Criteria in Solid Tumor) 1.1", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3-18 weeks depending on tumor response"
            }
        ], 
        "source": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Otsuka Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}